Skip to content

Study · Systematic review · n = 27,617 · 2025

8 results

Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials.

Sadraei S, Aarabi A, Rajai Firouzabadi S, Alinejadfard M, Mohammadi I, Jolfayi AG

BMC cardiovascular disorders21 Nov 2025Cited by 8 (Europe PMC)

PMID41272444 (opens in a new tab)PMCIDPMC12752371 (opens in a new tab)DOI10.1186/s12872-025-05278-3 (opens in a new tab)PepBankPUB-41272444
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of four RCTs, semaglutide reduced the risk of major adverse cardiovascular events compared with placebo.

    In plain wordsIn a pooled analysis of four trials, semaglutide lowered the risk of major cardiovascular events compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor adverse cardiovascular events (MACE)
    Study

    n = 27,617

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    RR
    0.81 NA
    MACE, semaglutide vs placebo

    Source sentences

    Summary
    There was a significant reduction in the risk of major adverse cardiovascular events (MACE) after administration of semaglutide (RR: 0.81, 95% CI: 0.74-0.88, p 2: 0.00%).
    2 context sentences
    Summary · context
    PubMed, Scopus, and Web of Science were searched comprehensively on February 26, 2024, to locate randomized controlled trials (RCTs) assessing semaglutide's impact on cardiovascular outcomes.
    Summary · context
    There were four RCTs involving 27,617 individuals (13,809 receiving semaglutide and 13,808 receiving placebo).
  2. 02HumanSystematic reviewSafety outcome

    In a meta-analysis of four RCTs, semaglutide led to fewer serious adverse events than placebo.

    In plain wordsIn a pooled analysis of four trials, semaglutide caused fewer serious adverse events than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseSerious adverse events
    Study

    n = 27,617

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    RR
    0.91 NA
    serious adverse events, semaglutide vs placebo

    Source sentences

    Summary
    The treatment also led to fewer serious adverse events (RR: 0.91, 95% CI: 0.88-0.94, p 2: 0.01%)
    2 context sentences
    Summary · context
    PubMed, Scopus, and Web of Science were searched comprehensively on February 26, 2024, to locate randomized controlled trials (RCTs) assessing semaglutide's impact on cardiovascular outcomes.
    Summary · context
    There were four RCTs involving 27,617 individuals (13,809 receiving semaglutide and 13,808 receiving placebo).
  3. 03HumanSystematic reviewSafety outcome

    In a meta-analysis of four RCTs, semaglutide was linked to a higher rate of treatment discontinuation than placebo.

    In plain wordsIn a pooled analysis of four trials, more people stopped treatment with semaglutide than with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseTreatment discontinuation
    Study

    n = 27,617

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    RR
    1.67 NA
    treatment discontinuation, semaglutide vs placebo

    Source sentences

    Summary
    though it was linked to a higher rate of treatment discontinuation (RR: 1.67, 95% CI: 1.27-2.21, p 2: 91.09%)
    2 context sentences
    Summary · context
    PubMed, Scopus, and Web of Science were searched comprehensively on February 26, 2024, to locate randomized controlled trials (RCTs) assessing semaglutide's impact on cardiovascular outcomes.
    Summary · context
    There were four RCTs involving 27,617 individuals (13,809 receiving semaglutide and 13,808 receiving placebo).
  4. 04HumanSystematic reviewEfficacy outcome

    In a meta-analysis of four RCTs, semaglutide reduced the risk of cardiovascular death compared with placebo.

    In plain wordsIn a pooled analysis of four trials, semaglutide lowered the risk of cardiovascular death compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseCardiovascular death
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, benefits were observed for particular findings such as cardiovascular death and nonfatal myocardial infarction.
    2 context sentences
    Summary · context
    PubMed, Scopus, and Web of Science were searched comprehensively on February 26, 2024, to locate randomized controlled trials (RCTs) assessing semaglutide's impact on cardiovascular outcomes.
    Summary · context
    There were four RCTs involving 27,617 individuals (13,809 receiving semaglutide and 13,808 receiving placebo).
  5. 05HumanSystematic reviewEfficacy outcome

    In a meta-analysis of four RCTs, semaglutide reduced the risk of nonfatal myocardial infarction compared with placebo.

    In plain wordsIn a pooled analysis of four trials, semaglutide lowered the risk of non-fatal heart attack compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseNonfatal myocardial infarction
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, benefits were observed for particular findings such as cardiovascular death and nonfatal myocardial infarction.
    2 context sentences
    Summary · context
    PubMed, Scopus, and Web of Science were searched comprehensively on February 26, 2024, to locate randomized controlled trials (RCTs) assessing semaglutide's impact on cardiovascular outcomes.
    Summary · context
    There were four RCTs involving 27,617 individuals (13,809 receiving semaglutide and 13,808 receiving placebo).
  6. 06HumanSystematic reviewEfficacy outcome

    In a meta-analysis of four RCTs, semaglutide had no significant effect on nonfatal stroke compared with placebo.

    In plain wordsIn a pooled analysis of four trials, semaglutide did not significantly change the risk of non-fatal stroke compared with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeNonfatal stroke
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    semaglutide showed no significant effect on nonfatal stroke, heart failure hospitalizations, or admissions for unstable angina.
    2 context sentences
    Summary · context
    PubMed, Scopus, and Web of Science were searched comprehensively on February 26, 2024, to locate randomized controlled trials (RCTs) assessing semaglutide's impact on cardiovascular outcomes.
    Summary · context
    There were four RCTs involving 27,617 individuals (13,809 receiving semaglutide and 13,808 receiving placebo).
  7. 07HumanSystematic reviewEfficacy outcome

    In a meta-analysis of four RCTs, semaglutide had no significant effect on heart failure hospitalizations compared with placebo.

    In plain wordsIn a pooled analysis of four trials, semaglutide did not significantly change hospital stays for heart failure compared with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeHeart failure hospitalizations
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    semaglutide showed no significant effect on nonfatal stroke, heart failure hospitalizations, or admissions for unstable angina.
    2 context sentences
    Summary · context
    PubMed, Scopus, and Web of Science were searched comprehensively on February 26, 2024, to locate randomized controlled trials (RCTs) assessing semaglutide's impact on cardiovascular outcomes.
    Summary · context
    There were four RCTs involving 27,617 individuals (13,809 receiving semaglutide and 13,808 receiving placebo).
  8. 08HumanSystematic reviewEfficacy outcome

    In a meta-analysis of four RCTs, semaglutide had no significant effect on admissions for unstable angina compared with placebo.

    In plain wordsIn a pooled analysis of four trials, semaglutide did not significantly change hospital admissions for unstable angina compared with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdmissions for unstable angina
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    semaglutide showed no significant effect on nonfatal stroke, heart failure hospitalizations, or admissions for unstable angina.
    2 context sentences
    Summary · context
    PubMed, Scopus, and Web of Science were searched comprehensively on February 26, 2024, to locate randomized controlled trials (RCTs) assessing semaglutide's impact on cardiovascular outcomes.
    Summary · context
    There were four RCTs involving 27,617 individuals (13,809 receiving semaglutide and 13,808 receiving placebo).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.